Hard to Swallow: Pharmacist-Led Strategies to Improve EoE Care


*On May 20, 2022, the FDA approved dupilumab to treat EoE in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds).*

ACTIVITY OVERVIEW

As the prevalence of eosinophilic esophagitis (EoE) continues to increase, pharmacists can play a pivotal role in its recognition, diagnosis, and recommendations for management. In this activity, a multidisciplinary panel discusses advances in EoE and the clinical implications of available and emerging therapies in long-term management.

Sponsored by

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

FACULTY

Gary W. Falk, MD, MS
Professor of Medicine
Division of Gastroenterology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA
Brian A. Hemstreet, PharmD, FCCP, BCPS
Associate Dean for Student Affairs and Professor
University of Colorado Skaggs School of Pharmacy and
Pharmaceutical Sciences
Aurora, CO
Erin Hamai Tom, PharmD, APh, MBA, BCACP
Pharmacy Supervisor, Specialty
Department of Pharmacy Services
UC Davis Health System
Sacramento, CA

FINANCIAL DISCLOSURE

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Gary W. Falk, MD, MS
Consulting Agreements: Allakos, Bristol Myers Squibb, CDX, Ellodi Pharmaceuticals, Lucid, Phathom Pharmaceuticals, Regeneron, Takeda
Grant/Research Support Recipient: Allakos, Arena, Bristol Myers Squibb, Ellodi Pharmaceuticals, Interpace, Lucid, Regeneron, Shire/Takeda

Brian A. Hemstreet, PharmD, FCCP, BCPS
Nothing to disclose

Erin Hamai Tom, PharmD, APh, MBA, BCACP
Speakers' Bureau: Janssen Biotech

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Topical steroids and biologic agents under investigation for EoE.

ACCREDITATION STATEMENTS

acpeThe Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity has been approved for 1.00 contact hour.

ACPE Universal Activity Number: 0396-0000-22-024-H01-P
Activity Type(s): Application

Published

April 29, 2022

Expires

April 29, 2023

TARGET AUDIENCE

This activity is intended for clinical pharmacists, specialty pharmacists, academic and community-based pharmacists, managed care pharmacists and retail pharmacists.

HOW TO OBTAIN CREDIT

This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

For questions, contact Karen Catino at kcatino@achlcme.org

GOAL

EoE has evolved from a rare condition to a disease that is commonly encountered and is now a burden for patients and the healthcare system. The natural history of EoE consists of chronic inflammation that may progress from childhood into adulthood, requiring long-term treatment. Pharmacists are well-positioned to assist patients in determining when to seek care for potential signs of EoE and must also understand its disease course to assist with care plans. Pharmacists require up-to-date knowledge of emerging approaches to counsel patients and ensure timely appropriate use as new therapies become available.

EDUCATIONAL OBJECTIVES

As a result of participating in this educational activity, clinicians should be able to:

  • Discuss pharmacist-led strategies to reduce delays in diagnosis for EoE
  • Recommend medication use practices based on the latest safety and efficacy data of current and emerging therapies targeting the histology and symptomology of EoE
  • Incorporate strategies to facilitate coordinated interdisciplinary EoE care to manage disease progression and improve patient quality of life

ACTIVITY OUTLINE

Ensuring a Prompt, Accurate Diagnosis of EoE: Role of the Pharmacist

  • Pathogenesis: inflammation and mediators
  • Increasing incidence and prevalence
  • Signs and symptoms  
  • Current recommended diagnostic algorithms
  • Strategies for early intervention

EoE: A Chronic Disease

  • Short- and long-term consequences  
  • Existing misconceptions
  • Need for maintenance therapy

Current and Emerging Treatment of EoE

  • Guideline recommendations
  • Medication use practices  
  • Role of the pharmacists in initiating, modifying and monitoring therapy
  • Current challenges for patients  
  • Investigational approaches and clinical trial efficacy and safety data
  • Future treatment paradigms

DISCLAIMER

All content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with ACPE Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5